Professor of Medicine
Campus mail
279 Msrb1, Durham, NC 27710
Phone
(919) 681-8551
Email address
loretta.que@duke.edu
My research interests focus on studying the role of nitric oxide and related enzymes in the pathogenesis of lung disease, specifically that caused by nitrosative/oxidative stress. Proposed studies are performed in cell culture and applied to animal models of disease, then examined in human disease where relevant. It is our hope that by better understanding the role of NO and reactive nitrogen species in mediating inflammation, and regulating cell signaling, that we will not only help to unravel the basic mechanisms of NO related lung disease, but also provide a rationale for targeted therapeutic use of NO.
Key words: nitrosative defense, lung injury, nitric oxide
Education and Training
- Pulmonary Fellow, Medicine, Duke University, 1993 - 1996
- Clinical Instructor, Medicine, Yale University, 1992 - 1993
- Medical Resident, Medicine, Yale University, 1989 - 1992
- M.D., The University of Chicago, 1989
Grants
- K01 - Coping with Asthma through Life Management (CALM)
- ALA LHC Boehringer Ingelheim Supplement
- Oxidative Stress and Regional Airway Remodeling and Fibrosis in Obese Asthma
- A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States
- RofLumilast or Azithromycin to preveNt COPD Exacerbations (RELIANCE)
- R01: CXCL10/CXCR3 regulation of ozone-induced epithelial permeability
- A double-blind, placebo-controlled, multi-centre, clinical trial to investigate the efficacy and safety of therapy with inhaled colistimethate sodium in the treatment of subjects with non-CF bronchiectasis chronically infected with P. aeruginosa
- Mitochondrial Redox Perturbations in Obese Allergic Asthma
- VTEU TO #132 Base - HHSN272201300017I TO 75N93019F00132 Task Area A - FY.2020.A1B1C1D1.0123 - Option 2.A
- Peep Mask study
- A Randomized Phase II Clinical Trial of L-Citrulline to Improve Asthma Control in Obese Late Onset Asthma
- EFC1580 BOREAS: A randomized double blind placebo controlled parallel group 52wk study to assess the efficacy, safety, and tolerability of Dupilumab in patients with moderate to severe COPD w/Type 2
- Mechanisms that Direct Airway Remodeling in Obese Asthma
- American Lung Association Airways Clinical Research Centers Network
- VTEU Task Order 22 16-0058 - Cost to Complete
- VTEU Task Order 16-0058.B1C1D1.0076 - Task D
- Research Training in Allergy and Clinical Immunology